Researchers at the American Cancer Society have found that nonelderly cancer survivors enrolled in high-deductible health plans are more likely to seek a change to a lower-cost prescription medication compared with those without a cancer history.
Researchers at the American Cancer Society have found that younger cancer survivors enrolled in high-deductible health plans are more likely to seek a change to a lower-cost prescription medication compared with those without a cancer history.
For their study, the authors identified 8931 adults from the National Health Interview Survey, conducted between 2011 and 2014, who reported being cancer survivors. The comparator population from the same survey were 126,287 individuals who had never been diagnosed with cancer. The authors documented the following outcomes as measures for change in prescription drug use due to financial constraints:
The authors adjusted their analyses for enrollee demographics, number of comorbidities, interaction between cancer history and number of comorbid conditions, and insurance coverage. The population was stratified based on age (nonelderly, 18 to 64 years; elderly, 65 years and older) and the time of diagnosis (recently diagnosed, less than 2 years; previously diagnosed, 2 years or earlier).
In the nonelderly population, financial constraints had a significant influence on both the recently diagnosed (31.6%) and previously diagnosed (27.9%) cancer survivors who reported changing their prescription drug use. Only 21.4% in the comparator group reported such a change. The authors also reported that more than 32% of nonelderly cancer survivors enrolled in high-deductible plans were likely to ask their doctors for lower cost medications, compared with 22.5% in the comparator group.
The authors recommended that policy changes should be directed to those cancer survivors who have multiple comorbid conditions and high-deductible health plans.
Reference
Zheng Z, Han X, Guy GP, et al. Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States [published online February 20, 2017]. Cancer. doi: 10.1002/cncr.30560.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More